跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 42,736 条关于
“IMMagine-3”
全部
42,736
临床试验
24,236
药物
4,683
机构
1,386
资讯
12,431
2年前
Kite and Arcellx to Initiate Phase III Trial of Anito-Cel for Multiple Myeloma
去年
Anitocabtagene Autoleucel Shows Durable Efficacy in Advanced Multiple Myeloma
去年
Anito-cel Shows Promise as Novel BCMA-Targeted CAR T Therapy for Multiple Myeloma
去年
Arcellx Reports 97% Response Rate in Multiple Myeloma CAR-T Trial, Targets 2026 Commercial Launch
去年
Novel CAR T-Cell Therapy Shows 97% Response Rate in Advanced Multiple Myeloma Trial
去年
Arcellx's Anito-Cel Shows High Response Rate in Relapsed/Refractory Multiple Myeloma
去年
Arlo-Cel and Antio-Cel Show Promise in Relapsed/Refractory Multiple Myeloma
9个月前
Kite's Anito-cel Shows 96% Response Rate in Pivotal Multiple Myeloma Trial, Supporting 2026 Launch Plans
去年
Arcellx Reports Strong CAR-T Clinical Data Despite 72% Revenue Drop in Q2 2025
去年
Kite Highlights CAR T-cell Therapy Portfolio with Positive Survival Outcomes at ASH 2024
第 1 页,共 1244 页
上一页
下一页